Researchers are looking at a combination of two types of monoclonal antibodies to treat advanced pancreatic cancer.
Researchers are testing a new antibody, a type of targeted therapy, in combination with standard treatment for pancreatic cancer in a phase III trial.
A clinical trial combines epigenetic therapy and immunotherapy to make immunotherapy more effective for patients with pancreatic and bile duct cancers.
A new clinical trial tests the safety of a monoclonal antibody and personalized cancer vaccine plus chemotherapy after surgery to remove pancreatic cancer.
Researchers are testing an immunotherapy drug approved for other advanced cancers for effectiveness against pancreatic cancer.
Wasting, or cachexia, is the focus of a clinical trial testing a cachexia immunotherapy treatment combined with standard pancreatic cancer treatment.
Researchers are combining immunotherapy and targeted therapy in a clinical trial for pancreatic cancer patients on platinum-based chemotherapy.
Dr. Deirdre Cohen discusses clinical trials that aim to improve the effectiveness of immunotherapy for pancreatic cancer.
Researchers are testing two monoclonal antibodies approved to treat melanoma plus radiation as a treatment for pancreatic cancer.
Dr. Mark O’Hara outlines a collaborative clinical trial of two immunotherapy agents–a checkpoint inhibitor and a monoclonal antibody–plus standard chemotherapy.
Dr. Luis Diaz provides a status check for immunotherapy treatments for pancreatic cancer, including an explanation of different types.
A clinical trial combines chemotherapy, immunotherapy, including a pancreas vaccine, and SBRT to stop locally advanced pancreatic cancer.
A clinical trial compares the effectiveness of two different types of immunotherapy with standard treatment after pancreatic cancer surgery.